What SELLAS Life Sciences Group, Inc. told the SEC could break it.

SELLAS has generated no product revenue (only licensing revenue from the 3D Medicines Agreement), has incurred net losses and used cash since inception, and has funded substantially all operations through equity and convertible-note proceeds; its convertible debt can require security interests in its assets and IP, and its stock traded between $0.92 and $3.77 in 2025 — so it must keep raising capital, exposing shareholders to dilution and funding risk.

“Since inception, we have incurred net losses, used net cash in our operations, and have funded substantially all of our operations through proceeds of the sale of equity securities and convertible notes.”

SELLAS's SLS009 program depends on a license agreement with GenFleet, and if that license is breached or terminated SELLAS could lose the ability to develop and commercialize SLS009; similarly its ability to enter future collaboration/licensing agreements for GPS depends on its intellectual-property rights — making its pipeline contingent on maintaining these third-party license relationships. (GenFleet captured as a named license edge.)

“We rely on a license agreement with GenFleet for the development of SLS009, and if this license is breached or otherwise terminated, we could lose the ability to continue the development and potential commercialization of SLS009.”

SELLAS's product candidates are in clinical development with uncertain FDA outcomes, and even if approved face U.S. drug-pricing pressure — Medicaid Drug Rebate Program rebates, extension of rebates to Medicaid managed care, and mandatory Medicare Part D discounts; it also flags 2025 U.S. tariffs (a 10% blanket tariff and 145% on Chinese imports) that could strain its manufacturers/suppliers and partners and disrupt clinical supply.

“in April 2025, the U.S. government announced a 10% tariff on product imports from almost all countries and individualized higher tariffs on certain other countries, including a 145% tariff on product imports from China.”

SELLAS owns no manufacturing facilities and depends entirely on third-party contract manufacturers for all raw materials, APIs and finished product candidates — with single sole-source CMOs for GPS (Polypeptide Group for the drug-substance peptides and Lyophilization Services of New England/PCI Pharma Services for the drug product) — and relies on a CRO for its Phase 3 GPS AML trial and other studies; loss of a sole CMO or CRO failure could disrupt its clinical supply and trials. (CMOs captured as named supplier edges.)

“We currently depend on third-party contract manufacturers for all of our required raw materials, active pharmaceutical ingredients, and finished product candidate for our clinical trials.”